The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.
 
Howard A. Burris
No Relationships to Disclose
 
Minal A. Barve
Research Funding - Mersana
 
Erika Paige Hamilton
Consulting or Advisory Role - Cascadian Therapeutics (Inst); Flatiron Health; Genentech/Roche (Inst); Pfizer (Inst)
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Cascadian Therapeutics (Inst); Curis (Inst); Genentech/Roche (Inst); Hutchison MediPharma (Inst); Kadmon (Inst); Lilly (Inst); Lycera (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Rgenix (Inst); Stem CentRx (Inst); Syndax (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Verastem (Inst); Zymeworks (Inst)
 
Aditya Bardia
Consulting or Advisory Role - Genentech; Novartis
 
Hatem Hussein Soliman
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Celgene
Research Funding - Amgen (Inst); Genentech/Roche (Inst)
 
Donna Jarlenski
Employment - Mersana
Stock and Other Ownership Interests - Mersana
 
Rebecca Mosher
Employment - Mersana; Novartis (I)
Stock and Other Ownership Interests - Mersana; Novartis; Novartis (I)
 
Donald Alan Bergstrom
Employment - Mersana
Leadership - Mersana
Stock and Other Ownership Interests - Mersana